Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis by Bartelink, IH et al.
A New Harmonized Approach to Estimate Busulfan Exposure 
Predicts Survival and Toxicity after Hematopoietic Cell 
Transplantation in Children and Young Adults: a Multicenter 
Retrospective Cohort Analysis
I.H. Bartelink, PhD PharmD.1, Arief Lalmohamed, PhD PharmD.2,3, Elisabeth M.L. van Reij, 
PharmD.2, Chris C. Dvorak, MD, PhD1, Rada M. Savic, PhD PharmD.1, Juliette Zwaveling, 
PhD PharmD.4, Robbert. G.M. Bredius, MD, PhD4, Antoine C.G. Egberts, PhD PharmD.2, M. 
Bierings, MD, PhD2, M. Kletzel, MD, PhD5, Peter J. Shaw, MD, MA6, Christa E. Nath, PhD 
PharmD.6, George Hempel, MD, PhD7, M. Ansari, MD, PhD8, M. Krajinovic, MD17, Yves 
Theoret, PhD17, Michel Duval, MD9, Ron J. Keizer, PhD PharmD.1,18, Henriette Bittencourt, 
MD, PhD9, Moustapha Hassan, MD, PhD19, Tayfun Güngör, MD10, Robert F. Wynn, MD11, 
Paul Veys, MD, PhD12, Geoff D.E. Cuvelier, MD13, Sarah Marktel, MD14, Robert Chiesa, MD, 
PhD12,14, Morton J. Cowan, MD1, Mary A. Slatter, MD, PhD15, Melisa K. Stricherz, PharmD16, 
Cathryn Jennissen, PharmD16, Janel R. Long-Boyle, PhD PharmD1, and Jaap Jan Boelens, 
MD, PhD2
1Departments of Allergy/Immunology/Bone Marrow Transplantation, Clinical Pharmacy, or 
Bioengineering & Therapeutic Sciences of the University of California San Francisco (UCSF), CA 
2Clinical Pharmacy department, Division pediatrics; Blood and Marrow Transplantation Program 
and/or Lab Translational Immunology of the University Medical Center Utrecht (UMCU), 
Netherlands 3Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University 
4Leiden University Medical Center (LUMC), the Netherlands 5Stem Cell Transplant Program Ann 
& Robert H. Lurie Children's Hospital of Chicago 6Children’s Hospital at Westmead, Sydney, 
NSW, Australia 7Universitätsklinikum at Münster, Germany 8Département de l'Enfant et de 
l'Adolescent, Hôpital des enfants (HUG) Genève, Switzerland 9Department of Pediatrics, Faculty 
of Medicine, University of Montreal, Montreal, Quebec, Canada 10Division of Stem Cell 
Transplantation and Children`s Research Center (CRC), University Children`s hospital Zürich, 
Switzerland 11The Royal Manchester Children’s Hospital, United Kingdom, United Kingdom 
12Great Ormond Street, Hospital for Children London, United Kingdom 13CancerCare Manitoba, 
Winnipeg, Canada 14Stem Cell Program, IRCCS San Raffaele Scientific Institute, Milan, Italy 
15The Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom 
16Hematopoietic Cell Transplant /Hematology/Oncology, University of Minnesota, Masonic 
Children's Hospital 17Centre de cancérologie Charles-Bruneau Centre de recherche pédiatrique - 
Hôpital Sainte-Justine Montréal, Québec, Canada 18InsightRX, a company developing dose 
optimization software for hospitals 19ECM, KFC, Laboratory Medicine, Karolinska Institutet, 
Stockholm, Sweden
Abstract
HHS Public Access
Author manuscript
Lancet Haematol. Author manuscript; available in PMC 2016 December 15.
Published in final edited form as:
Lancet Haematol. 2016 November ; 3(11): e526–e536. doi:10.1016/S2352-3026(16)30114-4.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Background—Intravenous-busulfan (IV-busulfan) combined with therapeutic drug monitoring to 
guide dosing improves outcomes after allogeneic hematopoietic cell transplantation (allo-HCT). 
The best method to estimate busulfan exposure and the optimal exposure in children/young adults 
remains unclear. We therefore evaluated three approaches to estimate IV-Bu exposure (expressed 
as cumulative-area-under-the-curve; AUC) and associated busulfan-AUC with clinical outcomes in 
children/young adults undergoing allo-HCT.
Methods—In this retrospective analysis, patients (0.1–30.4 years) receiving busulfan-based 
conditioning regimen from 15 centers were included. Cumulative AUC was calculated by 
numerical integration using non-linear mixed effect modeling (AUCNONMEM), non-compartmental 
analysis (AUC0-infinity and AUC to the end of the dose interval AUC0-tau) and by individual centers 
using a variety of approaches (AUCcenter). Main outcome of interest was event-free survival (EFS). 
Other outcomes of interest were overall survival, graft-failure, relapse, transplantation related 
mortality (TRM), acute toxicity (veno-occlusive disease (VOD) and/or acute graft versus-host 
disease (aGvHD), chronic GvHD (cGvHD) and cGVHD-free event-free survival (GEFS). 
Propensity score adjusted cox proportional hazard models, Weibull models, and Fine-Gray 
competing risk regressions were used.
Results—674 patients were included (41% malignant, 59% non-malignant) Estimated 2-year 
EFS was 69.7%. The median busulfan AUCNONMEM was 74.4 mg*h/L (CI95% 31.1–104.6 
mg*h/L). The median AUCNONMEM correlated poorly with AUCcenter (R2 = 0.254). Patients with 
optimal IV-busulfan AUC of 78–101 mg*h/L showed 81% EFS at 2 years compared to 66.1% and 
49.5% in the low (<78 mg*h/L) and high (>101 mg*h/L) busulfan AUC group respectively 
(P=0.011). Graft-failure/relapse occurred more frequently in the low AUC group (HR=1.75 
P<0.001). Acute toxicity, cGvHD and TRM was significantly higher in the high AUC group (HR 
1.69, 2.99 and 1.30), independent of indication.
Interpretation—These results demonstrate that improved clinical outcomes may be achieved by 
targeting the busulfan-AUC to 78–101 mg*h/L using a new validated pharmacokinetic-model for 
all indications.
Introduction
Allogeneic hematopoietic cell transplantation (allo-HCT) is standard of care treatment for a 
variety of malignant and nonmalignant disorders (e.g. immunodeficiencies, inherited 
metabolic diseases and hemoglobinopathies).1 Busulfan (Bu; Busulfex® for injection) is an 
alkylating agent routinely used in conditioning regimens prior to allo-HCT2. Intravenous 
(IV) busulfan shows large pharmacokinetic (PK) variability between children3–7 and the 
optimal exposure range in children has not been precisely defined. Higher exposure 
(expressed as area-under-the-curve; AUC) is associated with an increased risk of toxicity: 
e.g. mucositis, graft-versus-host disease (GvHD), veno-occlusive disease/sinusoidal 
obstructive syndrome (VOD/SOS) and transplant-related mortality (TRM).8–11 Low 
busulfan-AUC has been associated with a higher probability of graft-rejection or disease 
relapse.12–14 Therapeutic drug monitoring (TDM) to optimally individualize the dose of IV-
Bu is therefore often performed in children undergoing allo-HCT. However various targets 
(e.g. cumulative-AUC of 58–86 mg*h/L, or an AUC0–6 per dose of 900–1350µM*min or the 
concentration at steady state from 0–6 hours (Css) of 600–900 ng*m/L3,12,14,15) and 
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methods to estimate the AUC are used (e.g. numeric integration or trapezoidal rule, AUC 
from 0 to infinity; (AUC0-infinity), to the next dose (AUC0-tau), Css. In addition, only a few 
small, retrospective studies have been performed to determine the optimal AUC of busulfan 
in children/young adults.14,16–18 Recent studies in adults and children suggest that a 
busulfan-AUC of AUC0-inf 6000 µM*min/day × 4 (equivalent to a cumulative AUC of 100 
mg*h/L) reaches optimal efficacy.10,11,14 The optimal target may however vary with age, 
diagnosis, concomitant agents included in the preparative regimen and donor source.15,19 
Hence, there is an urgent need to comprehensively study busulfan exposure-response 
relationships to ensure optimal efficacy and prevent severe toxicity.
We therefore aimed to assess the relation between Busulfan exposure and clinical outcomes. 
To achieve this, we recalculated all AUCs by numerical integration using nonlinear mixed-
effects modeling methodologies NONMEM (AUCNONMEM) and non-compartmental 
analysis (AUC0-infinity and AUC0-tau), based on raw time-concentration data and AUC values 
estimated by site-specific preference for routine TDM. We subsequently conducted a 
retrospective analysis to relate exposure measures of busulfan to various allo-HCT 
outcomes, such as event free survival (EFS), aGvHD, VOD, graft-failure/disease relapse, 
and cGvHD.
Methods
Study Design and Patients
In this analysis, we included all patients who received their 1st allo-HCT with IV-busulfan as 
part of the conditioning regimen who were enrolled at fifteen pediatric transplant centers 
between 2000 and 2015, and from whom raw time-concentration data was available. The 
minimum follow-up for surviving patients was six months. Although analyzed in retrospect, 
clinical data were collected by the individual institutes prospectively and registered to 
clinical databases. Patients were included and data collected after written informed consent 
in accordance with the Declaration of Helsinki. Patients were transplanted according to site-
specific HCT protocols.
Busulfan Exposures and Evaluation of Methods to Calculate AUCs
All laboratories used validated methods to quantify busulfan in plasma, according to Good 
Laboratory Practices. In addition, cross validation of the methods between centers was 
previously performed.20
For patient care, busulfan exposures were calculated by individual centers using a variety of 
approaches (AUCcenter, Appendix Table 1). To better understand differences in exposure 
when estimates for AUC are derived using these different methods, we first compared AUCs 
estimated by the individual centers (AUCcenter) with the most commonly used approach: 
measuring AUC0-infinity by non-compartmental analysis using the individual raw time-
concentration data. The optimal approach to estimate AUCs for this analysis was considered 
using validated population PK models. Therefore exposures were re-estimated using non-
linear mixed effect modeling AUCNONMEM. as described in the Supplement: Statistical 
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analysis.4,5,21 The deviation and correlation and R2 between the estimates by AUCNONMEM 
with AUC0-infinity and AUC0-tau and Css were calculated using linear regression.
Outcomes and effect modifiers
Our main outcome of interest was event free survival (EFS) and was defined as survival 
from HCT to last contact whereby graft failure, relapse of disease, or death was regarded as 
events. All surviving patients were censored at day of last contact. Duration of follow-up 
was the time from allo-HCT to the last assessment for surviving patients or death.
We were also interested in graft-failure (defined as non-engraftment or rejection), disease 
relapse, transplant-related mortality (TRM), acute toxicity, chronic-GvHD (cGVHD), overall 
survival (OS) and cGVHD-free event-free survival (GEFS). TRM was defined as death 
unrelated to underlying disease. Acute toxicity was defined as moderate or severe VOD/SOS 
(graded according to Bearman),22 or acute-GVHD grade II–IV (aGVHD, diagnosed and 
graded according to Glucksberg).23 Chronic-GvHD (extensive or limited) was classified 
according to the Shulman criteria.24
Predictors of outcome considered were patient-specific variables (age at transplant, gender, 
cytomegalovirus (CMV) status), malignant/non-malignant disease First Complete Remission 
(CR1) or CR > 1 at baseline, donor-related factors (cell source, human leukocyte antigen 
(HLA)-disparity, match/mismatch), CMV status, conditioning regimen (one alkylating agent 
versus two or three alkylating agents), cumulative busulfan-AUC, use of serotherapy, 
aGvHD-prophylaxis/ ex vivo T cell depletion, calendar period (</>2006). Non-malignant 
was defined as having a diagnosis of primary immune deficiencies (PID), bone marrow 
failure, inherited metabolic diseases and hemoglobinopathies. Non-malignant disease were 
categorized by risk on graft failure: standard risk were classified; combined 
immunodeficiency (CID), severe combined immune deficiency (SCID), hemophagocytic 
lymphohistiocytosis (HLH), chronic granulomatous disease (CGD) or high-risk; inherited 
metabolic diseases and hemoglobinopathies). GvHD prevention was either ex-vivo T cell 
depletion of the graft of any immunosuppressive therapy given post-allo-HCT.
Statistical Considerations
The exposure-response models were built as described in Supplement: statistical analysis 
and Appendix Figure 1a. PK-PD analyses were performed using the regression analysis of 
survival data (PHREG) and procedures to estimate the parameters by maximum likelihood 
(LIFEREG) procedures from SAS software (version 9.3).
Role of Funding Sources—Drs. Long-Boyle and Bartelink received support by the 
UCSF CTSI Research Allocation Program and the UCSF Helen Diller Family 
Comprehensive Cancer Center and the Mt. Zion Health Fund of the University of California, 
San Francisco. Dr. Christa Nath is supported by The Leukaemia Research & Support Fund, 
The Children’s Hospital at Westmead.
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Results
Patient Characteristics
In total 790 patients (41% malignant, 59% non-malignant) were initially included (Appendix 
Figure 1a). Eighty-nine patients were excluded as no raw concentration-time profile could be 
provided (Appendix Figure 1a). 27 patients were excluded as they received a re-transplant. 
From the remaining 674 patients the median age at allo-HCT was 4.5 years (range, 0.1–30). 
Graft-source was bone marrow (BM) in 311 (46%), umbilical cord blood (UCB) in 208 
(31%) and peripheral blood stem cell (PBSC) in 144 (21%). The most frequently used 
conditioning regimen was busulfan/cyclophosphamide (n=363, 52%) followed by busulfan/
fludarabine (n=265, 38%) and busulfan/cyclophosphamide/melphalan (n=73, 10%). 
Busulfan was given as once daily in 271 patients (39%) and in 430 patients (61%) in 
multiple administrations per day. At 13 of 15 centers, dose adjustments of busulfan were 
performed with routine TDM and using variety of approaches to calculate busulfan 
exposures (Appendix Table 1).
Cumulative AUCs provided by the individual centers estimated using various different 
methods are listed (Appendix Table 1 right). Nine institutes used trapezoid AUC0-infinity, 
three used AUC0-tau and the other three were numeric integration by PK-models. All these 
centers used center-specific sampling schemes, used log-linear or linear trapezoidal rules 
during infusion and post-infusion, one institute used a test dose to estimate the cumulative 
exposures, in some institutes samples were repeated on one of the following dosing days and 
each institute varied in how to account for variability in exposure over time. The median 
AUC0-infinity estimated using the raw data in the current analysis was 3.6% higher than the 
AUC estimated by the individual centers (CI 95% −25% and +127%, Appendix Figure 2A). 
Due to large variability in estimation methods and sampling practices, cumulative AUCs 
estimated by the individual institutes showed a poor correlation compared to a standardized 
AUC0-infinity calculation method (Appendix Figure 2A, R2 = 0.254).
Final estimates of the NONMEM-model used to estimate individual AUCs of all raw PK-
data (except the data of UCSF as for this dataset was these specific raw concentration-time 
data were modeled previously)4 are shown (Appendix Table 2). Calculated median busulfan-
AUC by numerical integration using NONMEM was 74.4 mg*h/L (CI 95% 31.1–104.6 
mg*h/L). NONMEM Plots of individual predicted concentrations and observed 
concentrations versus time shows that the predictions by NONMEM decreased variability 
due to sampling errors and measurement errors. In addition, trapezoidal AUC under-predicts 
the actual AUC, which is better captured using AUCNONMEM (visualized in Figure 1). In 
addition, the models capture the increased exposure at day 2 to 4 in all patients. AUC0-infinity 
calculated using the raw data correlated well with AUC derived using NONMEM in respect 
of AUC prediction R2 of 0.741, but under-predicted the AUC by 8.3% (CI 95% −35 to 17%, 
Appendix Figure 2B). AUC0-tau lead to more pronounced under prediction of −25% (CI 
95% − 40 to −6%) compared to AUCNONMEM. Css and AUC0-tau showed the poorest 
correlation (R2=0.53, Appendix Figure 2C–2D). AUCs and Css values estimated by non-
compartmental analysis were relatively low if measured on one occasion only versus 
multiple occasions, after prolonged infusion times, longer period between infusion and the 
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first sample, and when limited sampling schemes were used. For these reasons 
AUCNONMEM was used to associate busulfan-exposure with outcomes.
Outcomes
Estimated EFS at 1 and 2-years post-allo-HCT was 72.6% and 69.7%, respectively. 
Estimated probability of graft-failure, TRM, and relapse at 2-years was 6.2%, 11.8%, and 
20.1, respectively. In the multivariate adjusted cox regression models busulfan-AUC 
(HR=0.64, P=0.04), malignant disease (HR=1.72, P=0.003), the addition of a third 
alkylating agent in the conditioning regimen (HR=1.6, P=0.049), and HLA-mismatch 
(HR=1.7, P=0.031) and year of transplantation (<2006, HR= 0.77 P=0.013) were 
independent predictors negatively influencing EFS (Appendix Table 3A).
To identify the optimal exposure, multivariate models correlating exposure with EFS were 
fitted. Given most events took place early after allo-HCT and decelerated with time, a 
Weibull model with decelerated hazard best described the baseline (Appendix Table 4). A 
fourth-order polynomial model was used to describe the association between cumulative 
AUC and EFS (Appendix Table 4, Figure 2A). Plots of model predictions versus observed 
events in the validation dataset shows that the model could well predict outcomes in new 
patients and the optimum determined using the validation set was within the 95% confidence 
interval of the originally defined optimum (Figure 2A, dotted line and Table 3). The Weibull 
model produced an optimal cumulative AUC of 90 mg*h/L (± 10% event probability 
optimum = 78–101 mg*h/L; Figure 2A). The EFS advantage of this ‘optimal exposure’ 
compared to the commonly used ‘historical’ busulfan target or an exposure above the 
‘optimal exposure’ is demonstrated in Figure 3. A low cumulative AUC (< 78 mg*h/L) 
increased the probability of graft failure and disease relapse (HR =0.57, P =0.004), while a 
high AUC (>101 mg*h/L) increased risk of TRM (HR=2.99, P<0.001; Figure 4A, Appendix 
Table 3A). This observation was similar in malignant and non-malignant disorders 
(Appendix Figure 3A+B).
In addition, twelve models were designed to evaluate how other patient-specific variables 
could influence the exposure-EFS relationship (Table 2). None of the variables significantly 
interacted with busulfan cumulative exposure and outcome parameters, which was 
confirmed in the validation set. Specifically, no difference was noted in either the shape of 
curve or the optimum busulfan-AUC between indications (Figure 2B), or number of 
alkylating agents (Appendix Figure 4A). In a subset analysis, EFS differed significantly 
between CID, SCID / HLH, CGD, Common variable immunodeficiency disorders (CVID) 
versus other non-malignant diseases (HR = 0.44, P = 0.02), but the optimal busulfan-AUC 
did not differ (Appendix Figure 4B). Also when SCID was analyzed separately the optimum 
remains the same for all groups (Appendix Figure 4C).
The estimated probability of acute toxicity, VOD, or grade 2–4 aGVHD at day 100 was 
22.9%, 9.1%, and 15.3%, respectively. Estimated probability of cGvHD (limited + 
extensive) at 2 years was 8.9%. A cumulative AUC above the ‘optimal exposure’ (> 101 
mg*h/L) was associated with increased acute toxicities (HR 1.69, P=0.013) but not with 
cGvHD (HR = 1.3, P=0.374, Table 3, Figure 4B+C). Busulfan-AUC and the use of three 
alkylating agents (Appendix Fig 5A,B,C) were independent predictors for acute toxicity 
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(HR=1.69, P<0.013 and HR=2.12, P<0.013), and TRM (HR=2.99, P<0.001 and HR=2.33, 
P=0.048, Appendix Table 3B). In addition, a transplant after 2006 showed decreased risk of 
acute toxicity (HR=1.28, P=0.048). The lowest probability of aGvHD, VOD and cGvHD 
was noted in the single alkylating agent group (Appendix Figure 5B+C).
The estimated probability of GEFS at 1 year was 66.8% and 62.6% at 2-years post-allo-
HCT. The shape of the curve and the optimal busulfan-AUC related to OS and GEFS was 
similar to the cumulative-AUC-EFS relationship with a HR of 0.71, P=0.016 and HR of 
0.57, P<0.001 for optimal exposure (78–101 mg*h/L, Table 3). The validation dataset shows 
the same association between cumulative-AUC and all outcomes of interest (Table 3).
Discussion
To our knowledge this is the largest PK-PD analysis in children/young adults to investigate 
the relation between exposure and clinical outcome. This study was done to identify the 
optimal therapeutic window for busulfan in pediatric/young adult allo-HCT, aiming to 
improve survival chance and reduce toxicity, including TRM and chronic GvHD. With the 
limitations of a retrospective cohort study taken into account, our data suggests that 
optimizing the target for cumulative busulfan-exposure has a significant effect on survival 
chances.
Our data suggests that it is important to standardize the approach to AUC estimation among 
transplant centers. AUC estimations vary when derived using different calculation 
approaches (population PK model based or traditional non-compartmental analysis-based). 
Results of traditional non-compartmental analysis-based calculations vary when using 
different PK sampling schemes (limited or intensive), infusion time and the specific 
equations used to calculate AUC for first dose or at steady-state, AUC0-inf, or AUC0-tau). 
Using a population approach by NONMEM to calculate AUCNONMEM limits the need to 
plan very specific sampling strategies and better approximates the actual cumulative AUC as 
it takes into account the exact time of infusion, accounts for errors in sampling and analysis 
and uses the individual clearance to calculate exposures. In addition, the models capture the 
increased exposure at day 2 to 4 in all patients. Using non-compartmental analysis, the latter 
effect can only be observed in patients when sampling occurs on multiple days. This 
suggests that for future studies it is important to harmonize the PK-estimation approach. 
This will also allow for better comparisons of busulfan-AUCs between institutions and help 
to facilitate prospective studies of individualized busulfan dosing strategies. Furthermore it 
reduces the number of blood samples required for AUC estimation, and will lead to better 
harmonization in clinical trial-design.25 Population PK models (based the published models) 
are accessible for clinical use (http://www.insight-rx.com or http://doseme.com.au).
This study demonstrates that the optimal busulfan-AUCNONMEM of 78–101 mg*h/L predicts 
higher EFS in children/young adults, compared to lower and higher exposure groups. This is 
in line with previous publications showing that high busulfan-AUC predicts acute toxicity 
and TRM8–10 and low busulfan-AUC leads to graft rejection or disease relapse.12–14 Our 
data demonstrates the majority of children/young adults will experience suboptimal 
busulfan-AUC when using the lower, currently applied ‘historical target’ of 58–86 mg*h/
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L13,15,26,27. Interestingly, studies conducted primarily in the US adult population target to 
higher cumulative busulfan-AUC (100 mg*h/L) either in combination with Cy or Flu, 
similar to the ‘optimal exposure’ identified in this study.10,11 Given the optimal exposure 
range is small and higher than current practice and high inter-patient variability in busulfan-
PK,25 TDM of busulfan is essential to achieve this narrow ‘optimal exposure’. The 95% 
confidence intervals of the models suggest that there is still some unexplained variability in 
outcomes. Therefore the optimized AUC should be considered with caution while applying 
the results to a single patient, such as in patients with high co-morbidity scores.
The exposure-EFS association was not influenced by any variable similar to previous studies 
in adults.10,11 In line with higher EFS in this study is a recent retrospective study in adults 
showing that fludarabine added to high dose busulfan (12.8 mg/kg versus 6.4 mg/kg) 
improved EFS due to lower probability on relapse.28 However, lower exposure is suggested 
to be sufficient in specific diseases: e.g. Gungur et al. reported in a prospective study that a 
cumulative busulfan-AUC of 45–65 mg/L*h combined with fludarabine resulted in a 2 year 
EFS of 89% in patients with CGD transplanted with BM/PBMC.16 In this study it would be 
important to understand what the AUC would be when analyzed in a harmonized way. In our 
cohort 2-year EFS in non-malignant diseases with standard risk of graft failure (CID, SCID, 
HLH, CGD or CVID) and treated with BM/PBSCs at AUC of 45–65 mg*h/L was 71% 
while at 78–101 mg*h/L this was 81%, suggesting that further optimization in these patients 
may be possible, but this finding needs prospective validation. As our subset analyses were 
limited by the heterogeneity of the study population, a prospective comparison between 
exposures in specific cohorts of non-malignant and malignant patients is needed to address 
this further.
Given the retrospective nature of this study we acknowledge there may be other covariates 
not evaluated in our analysis, such as generalized improvements in post-allo-HCT care, 
GvHD prophylaxis, or the clinical status and risk of co-morbidities (Center for International 
Blood and Marrow Transplant Research (CIBMTR) risk) of the patient prior to transplant, as 
this may have influenced decision making. These factors may have contributed to clinical 
outcomes. Also a small number of patients receive defibrotide as VOD prophylaxes (most in 
context of the prophylaxis trial, mostly in BuCyMeL).29 This may have influenced the 
endpoint VOD and potentially underestimated the risk of VOD. Other limitations are that for 
some variables like MRD status prior to allo-HCT, co-morbidity score, GvHD prophylaxis 
regimen, doses and exposures of each individual drug and ATG exposure before and after 
HCT30 may have influence on the outcomes but could not be included in this retrospective 
analysis. Using a large sample size from fifteen different HCT centers and by applying 
propensity adjusted analyses we adjusted for possible group selection of low and high 
busulfan-AUC patients. However, a randomized controlled trial in a specific disease groups 
may be the best way to confirm this higher and narrow ‘optimal exposure’ to busulfan.
In conclusion, the use of a new, harmonized and validated approach to measuring the 
busulfan-exposure aims to target a new, optimal cumulative busulfan exposure in children/
young adults undergoing allo-HCT. If this new approach is adopted, we expect higher 
survival chances with lower toxicity. Busulfan targeted to the ‘optimal cumulative busulfan 
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exposure’ combined with fludarabine further optimizes the balance between efficacy and 
toxicity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Example plots showing individual concentration observations derived in individuals (black 
dots), the individual predicted concentrations (blue shaded area) and non-compartmental 
analysis* to calculate the exposure (AUC
-infinity red shaded area and AUC- tau green shaded 
area)
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Figure 2. 
The polynomial Weibull model of the association between busulfan cumulative AUC and 
EFS (using uncensored data) is able to reproduce the central tendency in the observed EFS 
data, shown using Δ 5 mg*h/L AUC groups (dots) in the training (blue solid line) and 
internal validation dataset (blue dashed line) (A). The busulfan cumulative AUC and EFS 
model stratified by malignant (red solid line) and non-malignant (blue dashed line) 
underlying disease shows that the optimum AUC does not depend on indication (B). Shaded 
areas represent 95% confidence intervals.
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Figure 3. 
Kaplan-Meier plots of event-free survival stratified by busulfan cumulative AUC historic, 
the new target and the AUC above the new target, defined in the current study. Observed 
EFS (straight lines) including 95%CI (shaded areas) (Fine & Gray) and modelled events 
(dotted line, using the final Weibull model) are shown. Two year EFS at AUC of < 58 
mg*h/L was 52.3%, ‘historic target’ 58–86 mg*h/L was 66.1%, optimal IV-busulfan AUC of 
78–101 mg*h/L was 81% and >101 mg*h/L was 49.5%.
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Figure 4. 
The polynomial Weibull model of the association between busulfan cumulative AUC and 
graft failure/ disease relapse and TRM (using uncensored data) (A) and acute toxicity (at 6 
months post-HCT) (B) and cGvHD (C), with toxicities stratified by number of alkylating 
agents showed that a low cumulative exposure (<78 mg*h/L) increased the probability of 
graft failure/disease relapse, but an decreased the risk of TRM. A high cum AUC (>101 
mg*h/L) and the addition of a second or third alkylator increased the probability of VOD, 
aGvHD and cGvHD.
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Table 1
Characteristics of the study population (n=674)
Characteristic N (%)
Patient demographics
Age, years, median (range) 4.5 (0.1–30.4)
Year of transplant, year, median (range) 2008 (2000–2015)
Sex Males 425 (63%)
  missing, n = 0 Females 249 (37%)
CMV status recipient Negative 332 (49%)
  missing, n = 72 Positive 270 (40%)
Indication Malignant 274 (41%)
  missing, n = 0   AML 118 (18%)
  MDS 61 (9%)
  ALL 31 (5%)
  JMML 26 (4%)
  CML 17 (3%)
  Lymphoma, NHL 8 (1%)
  Infant ALL 5 (1%)
  Lymphoma, HD 4 (1%)
  Solid 3 (0%)
  Biphenotypical 1 (0%)
Non-malignant 400 (59%)
  Metabolic 123 (18%)
  Hb-pathy 75 (11%)
  CID 61 (9%)
  SCID 43 (6%)
  HLH / XLP 36 (5%)
  CGD 29 (4%)
  Congenital BMF 20 (3%)
  SAA 7 (1%)
  CVID 3 (0%)
  Autoimmune 2 (0%)
  Bone marrow failure 1 (0%)
Remission status prior to transplantation CR 1 69 (10%)
  missing, n = 164 (malignancies only) CR > 1 41 (6%)
Donor related factors
HLA disparity * Matched 373 (55%)
  missing, n = 50 Mismatched 251 (37%)
Source BM 311 (46%)
  missing, n = 11 UCB 208 (31%)
PBSC (+BM) 144 (21%)
CMV status donor Negative 380 (56%)
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Characteristic N (%)
  missing, n = 57 Positive 219 (32%)
Conditioning regimen
Number of alkylating agents in conditioning 1 252 (37%)
  missing, n = 0 2 352 (52%)
3 70 (10%)
GvHD prophylaxis / ex vivo T cell depletion No 0 (0%)
  missing, n = 15 Yes 659 (98%)
  GvHD prophylaxis 620 (92%)
  Ex vivo T cell depletion 39 (6%)
Serotherapy ** No 134 (20%)
  missing, n = 57 Yes 483 (72%)
Busulfan dosing regimen QD 267 (40%)
  missing, n = 0 Q6H 324 (48%)
Other 83 (12%)
Abbreviations: HLA, human leukocyte antigen; Bu, busulfan; Flu, fludarabine; Cy, cyclophosphamide; Mel, melphalan; QD, once daily; Q6H, four 
times daily; UBM, unrelated bone marrow; UCB, umbilical cord blood; PBSC, peripheral blood stem cell; AML, acute myeloid leukemia; ALL, 
acute lymphatic leukemia; CML, chronic myeloid leukemia; JMML, juvenile myelomonocytic leukemia; HD, Hodgkin’s disease; NHL, non-
Hodgkin lymphoma; MDS, myelodysplastic syndrome; CGD, chronic granulomatous disease; CID, combined immunodeficiency; BMF, bone 
marrow failure; CVID, common variable immune deficiency; HLH, hemophagocytic lymphohistiocytosis; XLP, X-linked lymphoproliferative 
disease; SAA, severe aplastic anemia; SCID, severe combined immunodeficiency; CR, Complete Remission; CMV, cytomegalovirus.
*
HLA matching was based on high-resolution typing for class I and class II (10 alleles) for bone marrow or peripheral blood stem cell donors. For 
cord blood donors, intermediate resolution criteria were used on 6 loci (low resolution for loci HLA-A, -B, and -DRB1 by high resolution typing). 
One or more allele or antigen mismatches was considered a mismatch.
**Serotherapy was defined as the use of alemtuzumab (Campath®) or ATG (Thymoglobulin®).
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Table 2
Multivariate Weibull models showing the optimal busulfan cumulative AUC target for EFS
training dataset (n = 449) validation set (n = 225)
Optimal AUC target (±10%)
(mg*hr/L)
P
value
model
P value
optimum
vs other stratum
Median optimal AUC
(mg*hr/L)
All patients 90 (78 – 101) 0.011 - 86
Malignant underlying disease
  No 88 (75 – 101) 0.035 - 89
  Yes 94 (82 – 103) 0.094 0.868 84
    By baseline remission
      CR 1 97 (80 – 110) 0.487 81
      CR 2+ 91 (79 – 107) 0.612 0.910 89
HLA disparity
  Matched 87 (77 – 96) 0.351 - 84
  Mismatched 94 (77 – 107) 0.095 0.891 87
By donor relationship
  MRD 87 (77 – 95) 0.032 - 90
  MMRD 90 (86 – 100) 0.446 0.930 84
  MUD 87 (71 – 103) 0.086 0.894 85
  MMUD 98 (83 – 112) 0.184 0.726 86
Number of alkylating agents
  1 92 (76 – 102) 0.102 - 85
  2 88 (80 – 100) 0.120 0.892 88
  3 92 (84 – 96) 0.224 0.930 88
Age at HSCT
  < 2 years 94 (77 – 106) 0.032 - 82
  2–5 years 84 (70 – 96) 0.112 0.801 89
  5–12 years 93 (85 – 103) 0.134 0.882 83
  > 12 years 92 (80 – 99) 0.198 0.891 89
HSCT source
  UCB 90 (80 – 100) 0.284 - 88
  BM / PBSC 89 (79 – 98) 0.408 0.791 83
By year of transplantation
  < 2006 89 (81 – 98) 0.043 - 86
  ≥ 2006 93 (79 – 106) 0.054 0.326 86
Busulfan dosing regimen
  Once daily dosing 89 (79 – 99) 0.700 - 85
  Four times daily dosing 93 (82 – 102) 0.530 0.811 87
By serotherapy
  No 88 (70 – 102) 0.326 - 90
  Yes 92 (73 – 104) 0.153 0.882 82
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Abbreviations: AUC, area under the curve; HLA, human leukocyte antigen; HSCT, hematopoietic stem cell transplantation; UCB, umbilical cord 
blood; BM, bone marrow; PBSC, peripheral blood stem cell; CR, Complete Remission
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